Jason Napodano, CFA has been with Zacks Investment Research since 2003 working as the Senior Pharmaceutical & Biotechnology analyst. In July 2009, Jason became Managing Director for the U.S. Institutional Equity Research Division.

Before joining Zacks, Jason Napodano served as Vice President and Senior Equity Analyst covering U.S. large-cap equities for Eastover Capital Management from 1999 to 2002. Prior to Eastover, Jason worked as a laboratory research scientist for TechLab Inc., a biotechnology company focused on the development of diagnostic kits and vaccines for infectious disease, from 1995 to 1998.

Jason Napodano holds a BS from Virginia Tech in Biochemistry and a MBA from Wake Forest University. Jason is also a Chartered Financial Analyst.

Brian Marckx is the Senior Medical Device Analyst with Zacks Investment Research.

Prior to joining Zacks, Brian worked as a high-yield bond analyst on Wachovia Securities' institutional trading desks where he specialized in the healthcare and industrials industries. Prior to that he was an analyst in corporate finance at First Union National Bank. Brian has covered the medical device, pharmaceutical and biotechnology industries since joining Zacks in 2007.

Brian Marckx has been quoted in numerous publications including The Wall Street Journal, Barron's, Bloomberg-Businessweek and Kilpinger. His work has also been cited in various market studies and working papers including those from Massachusetts Institute of Technology, Deloitte & Touche, and Pharmaceutical Manufacturing. Brian graduated with a B.S. in Finance from St. John Fisher College and received his MBA from Wake Forest University. Brian Marckx is also a Chartered Financial Analyst charterholder.

Steven Ralston, CFA, has over thirty years experience in the securities and investment industry, including Director of Research at First National Bank of Maryland, portfolio manager of General Accident's domestic and Canadian equity pension portfolios, and co-manager of Blackrock's $2.3 billion Large Cap Growth Fund. He received his initial investment training at Merrill Lynch and Fidelity & Deposit Company of Maryland.

John Tucker, PhD, MBA, joined Zacks Investment Research in 2013 as a Pharmaceutical and Biotechnology Analyst.

Prior to joining Zacks, John covered developments in infectious diseases and central nervous system disorders as a Biotechnology Analyst at Sagient Research (a division of Informa). Prior to 2010, John served in a variety of R&D roles in the pharmaceutical industry, pursuing drug discovery projects in metabolic disorders, multi-drug resistant bacterial infections, HIV infection, Alzheimer’s disease, and cancer.

John received his PhD under the mentorship of Nobel Laureate Donald J. Cram at UCLA in 1987, and returned to UCLA to complete his MBA in 2009.